Reducing provider workload while preserving patient safety via a two-way texting intervention in Zimbabwe's voluntary medical male circumcision program: study protocol for an un-blinded, prospective, non-inferiority, randomized controlled trial.
Adolescent
Adult
Aged
Attitude of Health Personnel
Circumcision, Male
/ adverse effects
Equivalence Trials as Topic
Health Knowledge, Attitudes, Practice
Health Personnel
/ organization & administration
Humans
Male
Middle Aged
Patient Acceptance of Health Care
Patient Safety
Prospective Studies
Text Messaging
Time Factors
Treatment Outcome
Volition
Workload
Young Adult
Zimbabwe
Healthcare delivery innovations
Mobile health
Post-operative follow-up
Voluntary medical male circumcision
Zimbabwe
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
23 Jul 2019
23 Jul 2019
Historique:
received:
11
01
2019
accepted:
24
05
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
6
2
2020
Statut:
epublish
Résumé
Surgical male circumcision (MC) safely reduces risk of female-to-male HIV-1 transmission by up to 60%. The average rate of global moderate and severe adverse events (AEs) is 0.8%: 99% of men heal from MC without incident. To reach the 2016 global MC target of 20 million, productivity must double in countries plagued by severe healthcare worker shortages like Zimbabwe. The ZAZIC consortium partners with the Zimbabwe Ministry of Health and Child Care and has performed over 120,000 MCs. MC care in Zimbabwe requires in-person, follow-up visits at post-operative days 2,7, and 42. The ZAZIC program AE rate is 0.4%; therefore, overstretched clinic have staff conducted more than 200,000 unnecessary reviews of MC clients without complications. Through an un-blinded, prospective, randomized, controlled trial in two high-volume MC facilities, we will compare two groups of adult MC clients with cell phones, randomized 1:1 into two groups: (1) routine care (control group, N = 361) and (2) clients who receive and respond to a daily text with in-person follow up only if desired or if a complication is suspected (intervention group, N = 361). If an intervention client responds affirmatively to any automated daily text with a suspected AE, an MC nurse will exchange manual, modifiable, scripted texts with the client to determine symptoms and severity, requesting an in-person visit if desired or warranted. Both arms will complete a study-specific, day 14, in-person, follow-up review for verification of self-reports (intervention) and comparison (control). Data collection includes extraction of routine client MC records, study-specific database reports, and participant usability surveys. Intent-to-treat (ITT) analysis will be used to explore differences between groups to determine if two-way texting (2wT) can safely reduce MC follow-up visits, estimate the cost savings associated with 2wT over routine MC follow up, and assess the acceptability and feasibility of 2wT for scale up. It is expected that this mobile health intervention will be as safe as routine care while providing distinct advantages in efficiency, costs, and reduced healthcare worker burden. The success of this intervention could lead to adaptation and adoption of this intervention at the national level, increasing the efficiency of MC scale up, and reducing burdens on providers and patients. ClinicalTrials.gov, NCT03119337 . Registered on 18 April 2017.
Sections du résumé
BACKGROUND
BACKGROUND
Surgical male circumcision (MC) safely reduces risk of female-to-male HIV-1 transmission by up to 60%. The average rate of global moderate and severe adverse events (AEs) is 0.8%: 99% of men heal from MC without incident. To reach the 2016 global MC target of 20 million, productivity must double in countries plagued by severe healthcare worker shortages like Zimbabwe. The ZAZIC consortium partners with the Zimbabwe Ministry of Health and Child Care and has performed over 120,000 MCs. MC care in Zimbabwe requires in-person, follow-up visits at post-operative days 2,7, and 42. The ZAZIC program AE rate is 0.4%; therefore, overstretched clinic have staff conducted more than 200,000 unnecessary reviews of MC clients without complications.
METHODS
METHODS
Through an un-blinded, prospective, randomized, controlled trial in two high-volume MC facilities, we will compare two groups of adult MC clients with cell phones, randomized 1:1 into two groups: (1) routine care (control group, N = 361) and (2) clients who receive and respond to a daily text with in-person follow up only if desired or if a complication is suspected (intervention group, N = 361). If an intervention client responds affirmatively to any automated daily text with a suspected AE, an MC nurse will exchange manual, modifiable, scripted texts with the client to determine symptoms and severity, requesting an in-person visit if desired or warranted. Both arms will complete a study-specific, day 14, in-person, follow-up review for verification of self-reports (intervention) and comparison (control). Data collection includes extraction of routine client MC records, study-specific database reports, and participant usability surveys. Intent-to-treat (ITT) analysis will be used to explore differences between groups to determine if two-way texting (2wT) can safely reduce MC follow-up visits, estimate the cost savings associated with 2wT over routine MC follow up, and assess the acceptability and feasibility of 2wT for scale up.
DISCUSSION
CONCLUSIONS
It is expected that this mobile health intervention will be as safe as routine care while providing distinct advantages in efficiency, costs, and reduced healthcare worker burden. The success of this intervention could lead to adaptation and adoption of this intervention at the national level, increasing the efficiency of MC scale up, and reducing burdens on providers and patients.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov, NCT03119337 . Registered on 18 April 2017.
Identifiants
pubmed: 31337414
doi: 10.1186/s13063-019-3470-9
pii: 10.1186/s13063-019-3470-9
pmc: PMC6651991
doi:
Banques de données
ClinicalTrials.gov
['NCT03119337']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
451Subventions
Organisme : FIC NIH HHS
ID : R21 TW010583
Pays : United States
Organisme : FIC NIH HHS
ID : 1R21TW010583-01
Pays : United States
Références
Stat Med. 2003 Jan 30;22(2):169-86
pubmed: 12520555
PLoS Med. 2005 Nov;2(11):e298
pubmed: 16231970
J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S123-6
pubmed: 17133195
Lancet. 2007 Feb 24;369(9562):643-56
pubmed: 17321310
Lancet. 2007 Feb 24;369(9562):657-66
pubmed: 17321311
AIDS Care. 2007 May;19(5):658-65
pubmed: 17505927
AIDS Care. 2008 Jul;20(6):677-82
pubmed: 18576169
AIDS Behav. 2010 Aug;14(4):778-84
pubmed: 19283464
Epidemiol Rev. 2010;32:56-69
pubmed: 20354039
Technol Health Care. 2010;18(2):137-44
pubmed: 20495253
AIDS Behav. 2010 Dec;14(6):1347-52
pubmed: 20700644
Lancet. 2010 Nov 27;376(9755):1838-45
pubmed: 21071074
AIDS. 2011 Mar 27;25(6):825-34
pubmed: 21252632
Trials. 2011 May 03;12:106
pubmed: 21539749
Mt Sinai J Med. 2011 May-Jun;78(3):406-18
pubmed: 21598267
PLoS Med. 2011 Nov;8(11):e1001132
pubmed: 22140367
Bull World Health Organ. 2012 May 1;90(5):390-2
pubmed: 22589574
J Telemed Telecare. 2012 Jul;18(5):273-81
pubmed: 22826375
PLoS One. 2012;7(9):e43832
pubmed: 22957034
Bull World Health Organ. 2012 Oct 1;90(10):773-81
pubmed: 23109745
J Am Med Inform Assoc. 2013 Jul-Aug;20(4):743-8
pubmed: 23144335
PLoS One. 2012;7(12):e46909
pubmed: 23236345
PLoS Med. 2013;10(2):e1001382
pubmed: 23424286
PLoS One. 2013 May 22;8(5):e63134
pubmed: 23717402
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e50-7
pubmed: 23846561
MMWR Morb Mortal Wkly Rep. 2013 Nov 29;62(47):953-7
pubmed: 24280914
AIDS Behav. 2014 Jul;18(7):1199-223
pubmed: 24563115
PLoS One. 2014 May 01;9(5):e95357
pubmed: 24788898
J Int AIDS Soc. 2014 Aug 01;17:19032
pubmed: 25095831
BMC Public Health. 2014 Aug 18;14:858
pubmed: 25134856
PLoS One. 2014 Aug 21;9(8):e100008
pubmed: 25144194
Eur J Cancer Care (Engl). 2014 Nov;23(6):750-6
pubmed: 25324023
J Int AIDS Soc. 2014 Nov 17;17:19275
pubmed: 25406951
J Acquir Immune Defic Syndr. 2015 May 1;69(1):e13-23
pubmed: 25942466
PLoS One. 2015 Sep 14;10(9):e0137376
pubmed: 26367187
PLoS One. 2015 Sep 25;10(9):e0138755
pubmed: 26405786
BMC Health Serv Res. 2016 Feb 17;16:61
pubmed: 26888178
J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S96-S100
pubmed: 27331599
J Int AIDS Soc. 2017 Feb 20;19(1):21394
pubmed: 28362066
Glob Health Action. 2018;11(1):1414997
pubmed: 29322867
PLoS One. 2018 Sep 7;13(9):e0203292
pubmed: 30192816
Health Serv Res. 1993 Dec;28(5):577-97
pubmed: 8270422